Pharmaceutical Research and Manufacturers of America (PhRMA)
Registered Principal Details
Business Or Interest:
Research and manufacturing pharmaceuticals organizations
Lobbying Interests:
All matters affecting the pharmaceuticals and health care industries
CEO Name:
John Castellani
Vice President, State Advocacy
Research and manufacturing pharmaceuticals organizations
Lobbying Interests:
All matters affecting the pharmaceuticals and health care industries
CEO Name:
John Castellani
Vice President, State Advocacy
Contact
KM
Kenneth McKay
950 F Street NW, Suite 300
Washington, DC 20004
(202) 835-3547
kmckay@phrma.org
http://www.phrma.org
950 F Street NW, Suite 300
Washington, DC 20004
(202) 835-3547
kmckay@phrma.org
http://www.phrma.org
Authorized Lobbyists
| Lobbyist Name | Exclusive Duties | Authorized On | Withdrawn On |
|---|---|---|---|
| Thomas E Moore | Exclusive Duties N/A | Authorized On 12/28/2016 | Withdrawn On N/A |
| Steven M Foti | Exclusive Duties N/A | Authorized On 12/28/2016 | Withdrawn On N/A |
| Saiza Elayda | Exclusive Duties N/A | Authorized On 2/20/2018 | Withdrawn On N/A |
Lobbying Interests
Legislative Bills/Resolutions
Assembly Bill 69
Relating to: access to investigational drugs, devices, and biological products and limitations on liability related to their use.
Bill Text and History
2/23/2017
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Comments
PhRMA is neutral on the bill provided participation by manufacturers remains optional and voluntary and the bill's liability provisions remain intact
Relating to: access to investigational drugs, devices, and biological products and limitations on liability related to their use.
Bill Text and History
Other
Notification Date2/23/2017
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Comments
PhRMA is neutral on the bill provided participation by manufacturers remains optional and voluntary and the bill's liability provisions remain intact
Assembly Bill 335
Relating to: fentanyl analogs and providing a criminal penalty.
Bill Text and History
2017 Wisconsin Act 60
6/28/2017
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Relating to: fentanyl analogs and providing a criminal penalty.
Bill Text and History
2017 Wisconsin Act 60
None
Notification Date6/28/2017
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Assembly Bill 620
Relating to: prescription drug cost reporting by manufacturers and providing a penalty. (FE)
Bill Text and History
1/15/2018
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Relating to: prescription drug cost reporting by manufacturers and providing a penalty. (FE)
Bill Text and History
Against
Notification Date1/15/2018
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Assembly Bill 800
Relating to: disclosures of prescription drug costs under health insurance policies and plans.
Bill Text and History
1/15/2018
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Relating to: disclosures of prescription drug costs under health insurance policies and plans.
Bill Text and History
For
Notification Date1/15/2018
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Senate Bill 531
Relating to: prescription drug cost reporting by manufacturers and providing a penalty. (FE)
Bill Text and History
1/15/2018
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Relating to: prescription drug cost reporting by manufacturers and providing a penalty. (FE)
Bill Text and History
Against
Notification Date1/15/2018
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Senate Bill 669
Relating to: disclosures of prescription drug costs under health insurance policies and plans.
Bill Text and History
1/15/2018
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Relating to: disclosures of prescription drug costs under health insurance policies and plans.
Bill Text and History
For
Notification Date1/15/2018
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Topics Not Yet Assigned A Bill Or Rule Number
Development, drafting or introduction of a proposal relating to
Health Carrier Prescription Drug Benefit Management Model Act
Health Carrier Prescription Drug Benefit Management Model Act
Action Intended To Affect
Both Legislative matter and rule
Notification Date
7/13/2018
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
7/13/2018
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to
SeniorCare
SeniorCare
Action Intended To Affect
Both Legislative matter and rule
Notification Date
5/22/2018
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
5/22/2018
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to
Access to prescription drugs
Access to prescription drugs
Action Intended To Affect
Legislative matter
Notification Date
1/24/2017
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Legislative matter
Notification Date
1/24/2017
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to
Medicaid budget
Medicaid budget
Action Intended To Affect
Legislative matter
Notification Date
1/24/2017
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Legislative matter
Notification Date
1/24/2017
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to
LRB 1201 re: synthetic opiates
LRB 1201 re: synthetic opiates
Action Intended To Affect
Legislative matter
Notification Date
1/24/2017
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Legislative matter
Notification Date
1/24/2017
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Total Lobbying Effort
| 2017 January - June |
2017 July - December |
2018 January - June |
2018 July - December |
Total | |
|---|---|---|---|---|---|
| Total Lobbying Expenditures | 2017 January - June $48,777.35 |
2017 July - December $51,120.00 |
2018 January - June $57,470.30 |
2018 July - December $28,360.12 |
Total $185,727.77 |
| Total Hours Communicating | 2017 January - June 21.00 |
2017 July - December 15.00 |
2018 January - June 18.00 |
2018 July - December 6.50 |
Total 60.50 |
| Total Hours Other | 2017 January - June 47.50 |
2017 July - December 87.50 |
2018 January - June 37.30 |
2018 July - December 37.35 |
Total 209.65 |
Percent Allocation of Lobbying Effort
Legislative Bills/Resolutions
Relating to: access to investigational drugs, devices, and biological products and limitations on liability related to their use.
| 2017 January - June |
2017 July - December |
2018 January - June |
2018 July - December |
Total |
|---|---|---|---|---|
| 2017 January - June |
2017 July - December 25% |
2018 January - June |
2018 July - December |
Total 10% |
Relating to: fentanyl analogs and providing a criminal penalty.
| 2017 January - June |
2017 July - December |
2018 January - June |
2018 July - December |
Total |
|---|---|---|---|---|
| 2017 January - June |
2017 July - December 50% |
2018 January - June |
2018 July - December |
Total 19% |
Budget Bill Subjects
No budget bill subjects found.
Administrative Rulemaking Proceedings
No administrative rulemaking proceedings found.
Topics Not Yet Assigned A Bill Or Rule Number
| 2017 January - June |
2017 July - December |
2018 January - June |
2018 July - December |
Total |
|---|---|---|---|---|
| 2017 January - June 25% |
2017 July - December |
2018 January - June |
2018 July - December |
Total 6% |
| 2017 January - June |
2017 July - December |
2018 January - June |
2018 July - December |
Total |
|---|---|---|---|---|
| 2017 January - June |
2017 July - December |
2018 January - June 10% |
2018 July - December |
Total 2% |
| 2017 January - June |
2017 July - December |
2018 January - June |
2018 July - December |
Total |
|---|---|---|---|---|
| 2017 January - June |
2017 July - December |
2018 January - June 20% |
2018 July - December 35% |
Total 10% |
| 2017 January - June |
2017 July - December |
2018 January - June |
2018 July - December |
Total |
|---|---|---|---|---|
| 2017 January - June |
2017 July - December |
2018 January - June 20% |
2018 July - December |
Total 4% |
Minor Efforts
(Time spent on matters each of which accounted for less than 10% of the organization's lobbying.)
Other Matters
Includes time spent on:
- Gubernatorial nominations
- Matters on which the organization made no lobbying communication